-
Adults (18-64 years)
-
General population
-
Elderly (≥65 years)
-
Hospital
-
Outpatient clinic
-
SARS-CoV-2
-
Post-COVID-19
-
Adults (18-64 years)
-
General population
-
Elderly (≥65 years)
-
Outpatient clinic
-
SARS-CoV-2
-
Post-COVID-19
-
Non pharmacological intervention
-
Rehabilitation
-
Adults (18-64 years)
-
General population
-
Elderly (≥65 years)
-
Hospital
-
Intensive care unit
-
SARS-CoV-2
-
Post-COVID-19
-
Pharmacological intervention
-
Monoclonal antibodies
-
Immunomodulator
-
Antineoplastic agent
-
Imatinib
-
Infliximab
-
General population
-
Outpatient clinic
-
SARS-CoV-2
-
Post-COVID-19
-
Adults (18-64 years)
-
General population
-
Healthcare workers
-
Hospital
-
Outpatient clinic
-
SARS-CoV-2
-
Post-COVID-19
-
Non pharmacological intervention
-
Rehabilitation
-
Adults (18-64 years)
-
General population
-
Elderly (≥65 years)
-
Hospital
-
Outpatient clinic
-
SARS-CoV-2
-
Post-COVID-19
-
Adults (18-64 years)
-
General population
-
Elderly (≥65 years)
-
Hospital
-
Outpatient clinic
-
SARS-CoV-2
-
Post-COVID-19
-
Adults (18-64 years)
-
General population
-
Elderly (≥65 years)
-
SARS-CoV-2
-
Post-COVID-19
-
Non pharmacological intervention
-
Rehabilitation
-
Neurostimulation
-
Adults (18-64 years)
-
General population
-
SARS-CoV-2
-
Post-COVID-19
-
Non pharmacological intervention
-
Rehabilitation